GB201116106D0 - Compounds and methods for the treatment of replicative senescence - Google Patents
Compounds and methods for the treatment of replicative senescenceInfo
- Publication number
- GB201116106D0 GB201116106D0 GB201116106A GB201116106A GB201116106D0 GB 201116106 D0 GB201116106 D0 GB 201116106D0 GB 201116106 A GB201116106 A GB 201116106A GB 201116106 A GB201116106 A GB 201116106A GB 201116106 D0 GB201116106 D0 GB 201116106D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- treatment
- beta
- integrin
- replicative senescence
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A method for inhibiting and/or reversing replicative senescence is provided comprising a step of administering a therapeutically effective amount of a compound which mediates allosteric modulation of beta 1 integrin to a subject in need thereof. Typically the allosteric modulation of beta 1 integrin results in beta 1 integrin assuming an intermediate affinity state conformation. The method of the present invention may be used in the treatment and/or prevention of ageing and ageing-related conditions.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201116106A GB201116106D0 (en) | 2011-09-17 | 2011-09-17 | Compounds and methods for the treatment of replicative senescence |
PCT/GB2012/052273 WO2013038196A1 (en) | 2011-09-17 | 2012-09-14 | Method for reversing or inhibiting replicative senescence |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201116106A GB201116106D0 (en) | 2011-09-17 | 2011-09-17 | Compounds and methods for the treatment of replicative senescence |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201116106D0 true GB201116106D0 (en) | 2011-11-02 |
Family
ID=44937454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB201116106A Ceased GB201116106D0 (en) | 2011-09-17 | 2011-09-17 | Compounds and methods for the treatment of replicative senescence |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201116106D0 (en) |
WO (1) | WO2013038196A1 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2912313B1 (en) | 2007-02-13 | 2012-07-06 | Rocher Yves Biolog Vegetale | COMPOSITION OF WHEAT AND ESCULIN EXTRACT AND USE IN COSMETICS. |
GB0703652D0 (en) * | 2007-02-26 | 2007-04-04 | Univ Bradford | Method for the allosteric modulation of beta1 integrin |
GB2478082B (en) * | 2007-02-26 | 2011-11-30 | Rehab Al-Jamal | Compounds and methods for the modulation of beta-1 integrin function to mediate tissue repair |
JP2010115131A (en) | 2008-11-12 | 2010-05-27 | Kao Corp | Evaluation method and method for screening skin ageing improving agent and skin aging preventive |
JP2011020951A (en) | 2009-07-15 | 2011-02-03 | Nagase & Co Ltd | Agent for ameliorating skin flabbiness |
-
2011
- 2011-09-17 GB GB201116106A patent/GB201116106D0/en not_active Ceased
-
2012
- 2012-09-14 WO PCT/GB2012/052273 patent/WO2013038196A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2013038196A1 (en) | 2013-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190270T1 (en) | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency | |
WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
HK1210957A1 (en) | Effluz inhibitor compositions and methods of treatment using the same | |
PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
WO2012142498A3 (en) | Mif inhibitors and their uses | |
PH12014501656A1 (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
EA201690753A1 (en) | COMBINATION INHIBITORS OF HISTONDEACETYLASE AND IMMUNOMODULATING MEDICINES | |
NZ718373A (en) | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor | |
MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
BR112015002275A2 (en) | processes and intermediates for the preparation of integrase inhibitors | |
MX339829B (en) | Methods for stabilizing joint damage in subjects using xanthine oxidoreductase inhibitors. | |
IL231234A0 (en) | Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases | |
IN2014CN00981A (en) | ||
EP2964750A4 (en) | Methods and compositions for the treatment and/or prevention of type 1 diabetes | |
EP2734188A4 (en) | Compositions and methods for the treatment of ocular surface allergies | |
GB201116106D0 (en) | Compounds and methods for the treatment of replicative senescence | |
GB201004761D0 (en) | Method | |
WO2013158698A3 (en) | Method treating scleroderma | |
GB201316698D0 (en) | Use of tri-substituted glycerol compounds for prevention and treatment of allo-immune disorders | |
TN2013000150A1 (en) | Co-crystals and salts of ccr3-inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |